Axsome Therapeutics (AXSM) Total Current Liabilities (2015 - 2026)

Axsome Therapeutics has disclosed Total Current Liabilities across 12 years of filings, most recently posting $439.2 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $439.2 million, up 80.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $439.2 million (up 80.07% YoY), and the FY2025 annual result was $378.8 million, up 64.64% from the prior year.
• Total Current Liabilities came in at $439.2 million for Q1 2026 at Axsome Therapeutics, up from $378.8 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $439.2 million in Q1 2026 to a low of $24.5 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $144.0 million (2024), against an average of $189.1 million.
• Peak annual rise in Total Current Liabilities reached 318.64% in 2022, while the deepest fall reached 13.22% in 2022.
• Axsome Therapeutics' Total Current Liabilities stood at $96.6 million in 2022, then jumped by 43.8% to $138.9 million in 2023, then jumped by 65.72% to $230.1 million in 2024, then surged by 64.64% to $378.8 million in 2025, then gained by 15.94% to $439.2 million in 2026.
• The last three Total Current Liabilities figures came in at $439.2 million (Q1 2026), $378.8 million (Q4 2025), and $360.3 million (Q3 2025), per Business Quant data.